The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ELCC 2019 | TKIs to treat EGFRm-positive NSCLC
Marina Garassino, MD, of National Cancer Institute of Milan, Milan, Italy, discusses the current treatment options for non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutations. Speaking at the European Lung Cancer Congress (ELCC) 2019, held in Geneva, Switzerland, Dr Garassino compares the efficacy and toxicity of three known EGFR tyrosine kinase inhibitors (TKIs): gefitinib, dacomitinib, and osimertinib, in treating EGFRm-positive NSCLC.
